Evidence map›Paper›PMID 26017803›Full record

ArticlePloS one2015

Impacts of autophagy-inducing ingredient of areca nut on tumor cells.

Ching-Yu Yen, Wei-Fan Chiang, Shyun-Yeu Liu, Chung-Chih Lin, Kuo-An Liao, Che-Yi Lin, Wan-Fang Hsieh, Yon-Chi Cheng, Kai-Cheng Hsu, Pin-Yen Lin and 4 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. [Relationship among areca nut, intracellular reactive oxygen species, and autophagy].Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology · 2020
    Review
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 1 country.

Ching-Yu YenDepartment of Dentistry, Taipei Medical University, Taipei, Taiwan; Department of Dentistry, National Defense Medical Center, Taipei, Taiwan; Oral and Maxillofacial Surgery Section, Chi Mei Medical Center, Tainan, Taiwan.
Wei-Fan ChiangOral and Maxillofacial Surgery Section, Chi Mei Hospital, Liouying, Taiwan; School of Dentistry, National Yang-Ming University, Taipei, Taiwan.
Shyun-Yeu LiuDepartment of Dentistry, Taipei Medical University, Taipei, Taiwan; Department of Dentistry, National Defense Medical Center, Taipei, Taiwan; Oral and Maxillofacial Surgery Section, Chi Mei Medical Center, Tainan, Taiwan.
Chung-Chih LinDepartment of Life Sciences and Institute of Genome Sciences, National Yang-Ming University, Taipei, Taiwan.
Kuo-An LiaoOral and Maxillofacial Surgery Section, Chi Mei Hospital, Liouying, Taiwan.
Che-Yi LinOral and Maxillofacial Surgery Section, Chi Mei Hospital, Liouying, Taiwan.
Wan-Fang HsiehDepartment of Biotechnology, Chia Nan University of Pharmacy, Tainan, Taiwan; Department of Medical Research, Chi Mei Medical Center, Tainan, Taiwan.
Yon-Chi ChengDepartment of Biotechnology, Chia Nan University of Pharmacy, Tainan, Taiwan; Department of Medical Research, Chi Mei Medical Center, Tainan, Taiwan.
Kai-Cheng HsuDepartment of Biotechnology, Chia Nan University of Pharmacy, Tainan, Taiwan; Department of Medical Research, Chi Mei Medical Center, Tainan, Taiwan.
Pin-Yen LinDepartment of Biotechnology, Chia Nan University of Pharmacy, Tainan, Taiwan; Department of Medical Research, Chi Mei Medical Center, Tainan, Taiwan.
Tai-Chi ChenDepartment of Medical Research, Chi Mei Medical Center, Tainan, Taiwan.
I-Ling LeeOral and Maxillofacial Surgery Section, Chi Mei Hospital, Liouying, Taiwan.
Mei-Huei LinDepartment of Biotechnology, Chia Nan University of Pharmacy, Tainan, Taiwan; Department of Medical Research, Chi Mei Medical Center, Tainan, Taiwan.
Young-Chau LiuDepartment of Medical Research, Chi Mei Medical Center, Tainan, Taiwan; Division of Natural Science, College of Liberal Education, Shu-Te University, Kaohsiung, Taiwan.
Chi Mei Medical Center · TWChia Nan University of Pharmacy and Science · TWNational Defense Medical Center · TWNational Yang Ming Chiao Tung University · TWShu-Te University · TWTaipei Medical University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Areca nut (AN) is a popular carcinogen used by about 0.6-1.2 billion people worldwide. Although AN contains apoptosis-inducing ingredients, we previously demonstrated that both AN extract (ANE) and its 30-100 kDa fraction (ANE 30-100K) predominantly induce autophagic cell death in both normal and malignant cells. In this study, we further explored the action mechanism of ANE 30-100K-induced autophagy (AIA) in Jurkat T lymphocytes and carcinoma cell lines including OECM-1 (mouth), CE81T/VGH (esophagus), SCC25 (tongue), and SCC-15 (tongue). The results showed that chemical- and small hairpin RNA (shRNA)-mediated inhibition of AMP-activated protein kinase (AMPK) resulted in the attenuation of AIA in Jurkat T but not in OECM-1 cells. Knockdown of Atg5 and Beclin 1 expressions ameliorated AIA in OECM-1/CE81T/VGH/Jurkat T and OECM-1/SCC25/SCC-15, respectively. Furthermore, ANE 30-100K could activate caspase-3 after inhibition of Beclin 1 expression in OECM-1/SCC25/SCC15 cells. Meanwhile, AMPK was demonstrated to be the upstream activator of the extracellular-regulated kinase (ERK) in Jurkat T cells, and inhibition of MEK attenuated AIA in Jurkat T/OECM-1/CE81T/VGH cells. Finally, we also found that multiple myeloma RPMI8226, lymphoma U937, and SCC15 cells survived from long-term non-cytotoxic ANE 30-100K treatment exhibited stronger resistance against serum deprivation through upregulated autophagy. Collectively, our studies indicate that Beclin-1 and Atg5 but not AMPK are commonly required for AIA, and MEK/ERK pathway is involved in AIA. Meanwhile, it is also suggested that long-term AN usage might increase the resistance of survived tumor cells against serum-limited conditions.

Indexed as

AMP-Activated Protein KinasesApoptosisApoptosis Regulatory ProteinsArecaAutophagyAutophagy-Related Protein 5Beclin-1Caspase 3Cell Line, TumorHumansJurkat CellsMAP Kinase Signaling SystemMembrane ProteinsMicrotubule-Associated ProteinsMouthMouth NeoplasmsAMP-Activated Protein KinasesApoptosis Regulatory ProteinsATG5 protein, humanAutophagy-Related Protein 5Beclin-1BECN1 protein, humanCaspase 3Membrane ProteinsMicrotubule-Associated ProteinsPlant Extracts

Identifiers

PMID26017803
PMCPMC4445909
OpenAlexW362944349

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.